HS Code:
The category of 3-Amino-3-methyl-1-butyne and (Dimethylamino)isopropyl chloride hydrochloride falls under specialized organic chemical compounds often used in pharmaceutical intermediates, research, and industrial applications. These compounds are niche products within the broader chemical sector, typically utilized in the synthesis of active pharmaceutical ingredients (APIs) or as reagents in chemical processes. Due to their specialized nature, trade in these products is limited to specific industries and is influenced by regulatory frameworks, intellectual property rights, and manufacturing capabilities.
Total Trade Volume
USD 15.7 million
Data from 2022
Source
UN Comtrade Database, International Trade Centre (ITC)
Average Rate
5.8%
Highest Rate
12% (imposed by certain developing economies for protecting domestic industries)
Lowest Rate
0% (under free trade agreements like EU-Japan EPA or USMCA)
Rising demand for pharmaceutical intermediates
Increased trade volume as global pharmaceutical production grows, particularly in generics and specialty drugs.
2021-2023
Shift towards Asia-Pacific manufacturing hubs
China and India are becoming dominant exporters due to lower production costs and established chemical manufacturing ecosystems.
2020-2022
Stringent regulatory frameworks
Increased compliance costs and barriers to entry in markets like the EU and US, affecting smaller exporters.
2019-2023
The European Union introduced stricter import controls on chemical intermediates, including mandatory REACH compliance for compounds like (Dimethylamino)isopropyl chloride hydrochloride.
March 2023
Potential delays and increased costs for exporters to the EU market, particularly affecting non-EU manufacturers.
Phase 1 trade agreement between the US and China reduced tariffs on certain chemical products, boosting exports of niche compounds from China to the US.
January 2022
Positive for Chinese exporters, with a reported 10% increase in trade volume for specialized chemicals.
India's Production Linked Incentive (PLI) scheme aims to boost domestic production of pharmaceutical intermediates, including compounds like 3-Amino-3-methyl-1-butyne.
April 2021
Enhanced export competitiveness for Indian manufacturers, potentially reshaping global supply chains.